Market Overview

Infinity Presents Updated Phase 1 Data Showing Encouraging Clinical Activity of IPI-145 in Chronic Lymphocytic Leukemia at ASCO

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced updated
Phase 1 data from an ongoing study of IPI-145, its potent, oral
inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in
patients with relapsed/refractory chronic lymphocytic leukemia (CLL), a
potentially fatal hematologic malignancy, or blood cancer. Data from the
study showed that IPI-145 was well tolerated, with a rapid onset of
clinical activity. These findings were presented today at the 2013
American Society of Clinical Oncology (ASCO) Annual Meeting. Based on
the tolerability and activity profile of IPI-145 observed to date,
Infinity also today announced that it has initiated a new expansion
cohort within its ongoing Phase 1 study to evaluate the safety, activity
and pharmacokinetics (PK) of IPI-145 dosed at 25 mg twice daily (BID) as

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (INFI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters